The contribution of micrornas to the inflammatory and neoplastic characteristics of erdheim–chester disease

Archive ouverte

Weissman, Ran | Diamond, Eli Louis | Haroche, Julien | Pillar, Nir | Shapira, Guy | Durham, B. H. | Buthorn, Justin J. | Cohen, Fleur | Ki, Michelle | Stemer, Galia | Ulaner, Gary A. | Amoura, Zahir | Emile, Jean François J.F. | Mazor, Roei David | Shomron, Noam | Abdel-Wahab, Omar I. | Shpilberg, Ofer | Hershkovitz-Rokah, Oshrat

Edité par CCSD ; MDPI -

International audience. The pathogenesis of histiocytic neoplasms is driven by mutations activating the MAPK/ERK pathway, but little is known about the transcriptional and post-transcriptional alterations involved in these neoplasms. We analyzed microRNA (miRNA) expression in plasma samples and tissue biopsies of Erdheim–Chester disease (ECD) and Langerhans cell histiocytosis (LCH) patients. In silico analysis revealed a potential role of miRNAs in regulating gene expression in these neoplasms as compared with healthy controls (HC). NanoString analysis revealed 101 differentially expressed plasma miRNAs in 16 ECD patients as compared with 11 HC, 95% of which were downregulated. MiRNAs-15a-5p,-15b-5p,-21-5p,-107,-221-3p,-320e,-630, and let-7 family miRNAs were further evaluated by qRT-PCR in an extended cohort of 32 ECD patients, seven LCH and 15 HC. Six miRNAs (let-7a, let-7c, miR-15a-5p, miR-15b-5p, miR-107 and miR-630) were highly expressed in LCH plasma and tissue samples as compared with ECD. Pathway enrichment analysis indicated the miRNA contribution to inflammatory and pro-survival signaling pathways. Moreover, the let-7 family members were downregulated in untreated ECD patients as compared with HC, while treatment with MAPK/ERK signaling inhibitors for 16 weeks resulted in their upregulation, which was in parallel with the radiologic response seen by PET-CT. The study highlights the potential contribution of miRNA to the inflammatory and neoplastic characteristics of ECD and LCH.

Suggestions

Du même auteur

MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis

Archive ouverte | Weissman, Ran | CCSD

International audience. Erdheim–Chester disease (ECD) is characterized by excessive production and accumulation of histiocytes within multiple tissues and organs. ECD patients harbor recurrent mutations of genes ass...

ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition

Archive ouverte | Kemps, Paul Geraeds | CCSD

International audience. ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity ...

Childhood-onset Erdheim-Chester disease in the molecular era: clinical phenotypes and long-term outcomes of 21 patients

Archive ouverte | Pegoraro, Francesco | CCSD

International audience

Chargement des enrichissements...